Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Tribute Pharmaceuticals Canada Inc. | tbuff_ex991.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2015
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
|
Ontario, Canada
|
001-31198
|
Not Applicable
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip Code)
(519) 434-1540
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act.
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On May 12, 2015, Tribute Pharmaceuticals Canada Inc. (the “Company”) issued a press release regarding the financial results for the first quarter of fiscal 2015. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Tribute Pharmaceuticals Canada Inc. Press Release, dated May 12, 2015
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 14, 2015
|
TRIBUTE PHARMACEUTICALS CANADA INC.
|
|
By: /s/ Scott Langille
|
|
|
Name: Scott Langille
|
|
|
Title: Chief Financial Officer
|
3
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
99.1
|
Tribute Pharmaceuticals Canada Inc. Press Release, dated May 12, 2015
|
4